A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.
| Excerpt | Reference |
|---|
| "Vitiligo is a common pigment disease that is difficult to treat." | ( Cui, J; Shen, LY; Wang, GC, 1991) |
| "Vitiligo is an acquired disease characterized by depigmentation of the skin due to destruction of melanocytes." | ( Held, JL; Kohn, SR, 1990) |
| "Vitiligo is a human disorder which destroys pigment cells in the skin, ears, eyes, and meningeal tissues and has often been associated with a variety of autoimmune disorders." | ( Amornsiripanitch, S; Barnes, LM; Nordlund, JJ; Rheins, LA; Trinkle, LS, 1988) |
| "Vitiligo is characterized by depigmentation in large or small areas of the skin." | ( Dunn, JF, 1986) |
| "The treatment of vitiligo is still unsatisfactory in many patients." | ( Frenk, E, 1986) |
| "Vitiligo is a common, acquired condition of unknown etiology." | ( Ajam, ZA; al-Aboosi, MM, 1995) |
| "Vitiligo is a pigmentary disorder of unknown cause characterized by depigmented patches due to destruction of melanocytes." | ( Hann, SK; Im, S; Kim, HI; Kim, NS; Park, YK, 1994) |
| "Vitiligo is a disease of unknown origin that causes destruction of melanocytes in the skin, mucous membranes, the eyes, and occasionally in hairbulbs and in the ears." | ( Grimes, P; Halder, RM; Nordlund, JJ, 1993) |
| "The major type of vitiligo is considered to be an autoimmune disorder." | ( Kaneko, F; Nihei, Y; Nishibu, A, 1998) |
| "Nonsegmental-type vitiligo is associated with autoimmune diseases while segmental-type vitiligo results from the dysfunction of sympathetic nerves in the affected area." | ( Chang, HR; Wu, BN; Wu, CS; Yu, CL; Yu, HS, 2000) |
| "The etiology of vitiligo is still being debated, although neural factors seem to play a pivotal role in its pathogenesis." | ( Cucchi, ML; Frattini, P; Orecchia, G; Santagostino, G, 2000) |
| "Leprosy and vitiligo are common affections in the West Indies." | ( Boisseau-Garsaud, AM; Garsaud, P; Helenon, R; Quist, D; Saint-Cyr, I; Vezon, G, 2000) |
| "Vitiligo is an acute disease of skin with inflammation which means damage of melanocites, their defined partial paint lack." | ( Aigner, Z; Józsa, P; Kata, M, 2000) |
| "Vitiligo is a skin and hair disorder characterized by circumscribed depigmented lesions due to lack of melanocytes in the respective areas." | ( Caroli, CC; Garbe, C; Knauss-Scherwitz, E; Lang, KS; Moris, A; Muhm, A; Rammensee, HG; Schittek, B; Stevanovic, S; Wernet, D, 2001) |
| "Vitiligo is a common skin disease characterized by the presence of well circumscribed, depigmented, milky white macules devoid of identifiable melanocytes." | ( Ardigó, M; Badulli, C; Borroni, G; Brazzelli, V; Campanelli, R; Garbelli, S; Giachino, C; Lantelme, E; Mantovani, S; Martinetti, M; Necker, A; Palermo, B, 2001) |
| "Vitiligo is an acquired skin disorder caused by the disappearance of pigment cells from the epidermis that gives rise to well defined white patches which are often symmetrically distributed." | ( Njoo, MD; Westerhof, W, 2001) |
| "Vitiligo is associated with high psychiatric morbidity." | ( Gupta, N; Handa, S; Kaur, I; Malhotra, R; Mattoo, SK, 2002) |
| "Vitiligo is a hypopigmented skin condition that usually requires a combination of treatment options." | ( Camacho, F; Mazuecos, J, 2002) |
| "Common generalized vitiligo is an acquired depigmenting disorder characterized by a chronic and progressive loss of melanocytes from the epidermis and follicular reservoir." | ( Cario Andre, M; Gauthier, Y; Taïeb, A, 2003) |
| "Vitiligo is a disfiguring skin disease." | ( Arroyo, MP; Tift, L, 2003) |
| "Vitiligo is a common depigmentation disorder thought to result from autoimmune destruction of melanocytes." | ( Barber, BH; DeBenedette, MA; Mandelcorn-Monson, RL; Sambhara, S; Shear, NH; Spaner, D; Yau, E, 2003) |
| "Vitiligo is an acquired skin disorder that is characterized by well-defined, often symmetric white patches." | ( Kawalek, AZ; Phelps, RG; Spencer, JM, 2004) |
| "Vitiligo is an idiopathic leukoderma often with a progressive course causing destruction of melanocytes." | ( Christova, P; Trashlieva, M; Valkova, S, 2004) |
| "Vitiligo is a common pigmentary disorder of the skin with selective destruction of melanocytes." | ( Altinyazar, HC; Armutcu, F; Gürel, A; Koca, R, 2004) |
| "Vitiligo is an autoimmune disorder characterized by loss of pigmentation." | ( Chamlin, SL; Farley-Li, J; Lin, P; Mancini, AJ; Paller, AS; Silverberg, NB; Travis, L; Wagner, AM, 2004) |
| "Childhood vitiligo is a common disorder of pigmentation in India." | ( Dogra, S; Kanwar, AJ; Parsad, D, 2004) |
| "Vitiligo is an acquired hypomelanotic skin disorder resulting from the loss of functional melanocytes from the cutaneous epidermis and autoimmunity has been suggested to play a part in its pathogenesis." | ( Akhtar, S; Blomhoff, A; Cantón, I; Gavalas, NG; Gawkrodger, DJ; Kemp, EH; Watson, PF; Weetman, AP, 2005) |
| "Vitiligo is an acquired pigmentary disorder characterized by depigmentation of skin and hair." | ( Chang, CH; Chen, GS; Chiou, MH; Lan, CC; Wu, CS; Yu, HS, 2005) |
| "Vitiligo is a skin disorder characterized by depigmented macules secondary to melanocyte loss." | ( Avanzini, MA; Bernabei, P; Borroni, G; Brazzelli, V; Da Prada, GA; Garbelli, S; Giachino, C; Mantovani, S; Palermo, B; Scoccia, E, 2005) |
| "Vitiligo is a frequent dyschromia, characterized by achromic macules that reflect the absence of melanocytes." | ( Almeida, P; Borrego, L; Cameselle, D; Hernández, B; Luján, D; Rodríguez-López, J, 2005) |
| "Vitiligo is a skin disease characterized by loss of normal pigmentation in the skin." | ( Iacovelli, P; Leone, G; Pacifico, A; Paro Vidolin, A; Picardo, M, 2006) |
| "Treatment of vitiligo is a challenge." | ( Kaur, I; Kumar, B; Kumaran, MS, 2006) |
| "Vitiligo is a common, idiopathic, acquired, depigmenting disease characterized by loss of normal melanin pigments in the skin." | ( Arca, E; Erbil, AH; Koç, E; Kurumlu, Z; Sezer, E; Taştan, HB, 2006) |
| "Vitiligo is an acquired pigmentary skin disorder that affects 0." | ( Sitek, JC, 2006) |
| "Vitiligo is characterized by the absence of melanocytes in skin and hair follicles." | ( Sitek, JC, 2006) |
| "Vitiligo is an acquired, pigmentary skin disorder which is disfiguring and difficult to treat." | ( Dawid, M; Grassberger, M; Veensalu, M; Wolff, K, 2006) |
| "Vitiligo is a chronic disease that mostly affects children and young adults." | ( Alirezaie, NS; Dowlati, Y; Farnaghi, F; Firooz, A; Seirafi, H; Vasheghani-Farahani, A, 2007) |
| "Vitiligo is a chronic illness of a yet unknown etiology, characterized by an acquired and progressive depigmentation of the skin." | ( Poleo-Romero, AG; Rojas-Urdaneta, JE, 2007) |
| "Vitiligo is a skin disease with a worldwide prevalence ranging from 0." | ( Buchholtz, S; Forschner, T; Stockfleth, E, 2007) |
| "Vitiligo is a skin disorder affected by genetic, environmental, local and endocrine factors." | ( Choi, CP; Chung, JH; Kim, HJ; Kim, YI; Lee, JW; Lee, MH; Uhm, YK; Yoon, SH, 2007) |
| "Vitiligo is characterized by the selective destruction of melanocytes resulting in patches of skin depigmentation." | ( Craveiro Leite, AA; Souza Leite, RM, 2007) |
| "Common generalized vitiligo is an acquired depigmenting disorder characterized by a chronic and progressive loss of melanocytes from the epidermis and hair follicles." | ( Cario-André, M; Gauthier, Y; Pain, C; Taïeb, A, 2007) |
| "Vitiligo is an acquired depigmenting disease with uncertain aetiopathogenesis, possibly associated with oxidative stress." | ( Calzavara, PG; Dell'Anna, ML; Leone, G; Mastrofrancesco, A; Ottaviani, M; Picardo, M; Sala, R; Venturini, M; Vidolin, AP; Westerhof, W, 2007) |
| "Vitiligo is a common pigmentary disorder with great cosmetic and psychological morbidity and an unpredictable course." | ( Bhatnagar, A; De, D; Kanwar, AJ; Parsad, D, 2007) |
| "Treatment of vitiligo is a challenge, especially in children." | ( Bröcker, EB; Hamm, H; Hartmann, A, 2008) |
| "Vitiligo is an acquired leukoderma that results from the loss of epidermal melanocytes, and is characterized by macules and patches of depigmented skin." | ( Hamzavi, IH; Hexsel, CL; Mahmoud, BH, 2008) |
| "Vitiligo is an acquired skin disease characterized by white areas on the skin." | ( Arican, O; Kurutas, EB, 2008) |
| "Vitiligo is characterized by progressive skin depigmentation resulting from an autoimmune response targeting epidermal melanocytes." | ( Le Poole, IC; Luiten, RM, 2008) |
| "Vitiligo is a hypopigmentation disorder affecting 1 to 4% of the world population." | ( Boon, HS; Szczurko, O, 2008) |
| "Vitiligo is a pigmentary disorder which may have disfiguring consequences." | ( Cazzaniga, S; Chatenoud, L; Girolomoni, G; Marchesi, L; Naldi, L; Reseghetti, A; Sassi, F; Tessari, G, 2008) |
| "Vitiligo is a common, acquired, depigmenting disease of the skin." | ( Bak, H; Chang, SE; Choi, CW; Choi, JH; Huh, CH; Kim, BJ; Kim, CW; Kim, MN; Kim, SE; Mun, SK; Park, HS, 2008) |
| "Vitiligo is a common skin disease which is difficult to treat." | ( García Bustínduy, M; Noda Cabrera, A; Rodríguez-Martín, M; Sáez Rodríguez, M, 2009) |
| "Vitiligo is an acquired, pigmentary skin disorder which is disfiguring and difficult to treat." | ( Huang, B; Lu, LJ; Wei, XD; Xu, AE; Zhang, DM, 2009) |
| "The pathogenesis of vitiligo is complex and not well understood." | ( Boissy, RE; Spritz, RA, 2009) |
| "Vitiligo is an acquired dermatological condition that is characterized by depigmentation of patches of skin." | ( Dytoc, MT; Lauzon, G; Maguiness, S; Taher, ZA, 2009) |
| "Vitiligo is an acquired skin disorder characterised by white (depigmented) patches in the skin, due to the loss of functioning melanocytes." | ( Matin, R, 2008) |
| "Vitiligo is a skin disorder characterized by loss of functional melanocytes." | ( Bani, D; Baroni, G; Berti, E; Berti, S; Fabbri, P; Lotti, T; Massi, D; Moretti, S; Nassini, R, 2009) |
| "Vitiligo is an acquired skin disease, characterized by white areas on the skin due to loss of functional melanocytes." | ( Gupta, S; Khan, R; Satyam, A; Sharma, A; Sharma, VK, 2009) |
| "Vitiligo is an acquired condition that presents as sharply demarcated white macules." | ( El Hoseny, SM, 2010) |
| "Vitiligo is characterized by a patchy loss of inherited skin color affecting approximately 0." | ( Chavan, B; Gibbons, NC; Salem, MM; Schallreuter, KU; Shalbaf, M; Thornton, JM, 2009) |
| "Vitiligo is a common acquired idiopathic hypomelanotic disorder characterized by circumscribed depigmented maculae." | ( Chang, WY; Cheng, GS; Huang, CC; Lo, YH; Wu, CS, 2010) |
| "Vitiligo is a mucocutaneous pigmentary disorder with worldwide distribution." | ( Chen, HD; Gao, XH; Liu, YB; Liu, YY; Ma, L; Mchepange, UO; Zhang, L, 2010) |
| "Vitiligo is an acquired pigmentary disorder treated frequently with PUVA and narrowband UVB phototherapy." | ( Coelho, JD; Ferreira, A, 2010) |
| "Vitiligo is a disease characterized by the loss of melanocytes, resulting in progressive depigmentation of skin, and areas of normally pigmented skin can be of cosmetic concern." | ( Di Nuzzo, S; Masotti, A, 2010) |
| "Vitiligo is a multifactorial disorder characterized by the appearance of white maculae that may spread over the entire body skin." | ( Brescia, S; Dellambra, E; Guerra, L; Raskovic, D, 2010) |
| "Vitiligo is an autoimmune disease characterized by depigmented patches and macules." | ( Abdo, AA; Alajlan, A; Binamer, Y; Hamadah, I; Sanai, FM, 2010) |
| "Vitiligo is the most common pigmentation-related disorder worldwide." | ( Alpay, K; Bahadır, S; Okten, A; Uncu, S; Yaylı, S, 2011) |
| "Vitiligo is a relatively common acquired skin depigmentary disease with a complex presentation, therapy, and etiology." | ( Boissy, RE; Nordlund, JJ, 2011) |
| "While vitiligo is usually idiopathic, some cases are caused by chemicals." | ( Broding, HC; Brüning, T; Fartasch, M; Monsé, C, 2011) |
| "Vitiligo is an acquired depigmenting disorder caused by the destruction of melanocytes." | ( Pandey, SS; Singh, S; Singh, U, 2011) |
| "Vitiligo is the most prevalent pigmentary disorder which occurs worldwide, with an incidence rate between 0." | ( Bagherani, N; Omidian, M; Yaghoobi, R, 2011) |
| "Vitiligo is a depigmenting disorder of the skin that is characterized by the loss of functional melanocytes from the lesional sites." | ( Begum, R; Dwivedi, M; Gokhale, RS; Gupta, S; Kar, HK; Laddha, NC; Rani, R; Sharma, P; Sharma, VK; Singh, A; Tembhre, MK, 2012) |
| "Vitiligo is a common skin disease characterized by loss of normal melanin pigments in the skin and its pathogenesis is still unclear." | ( Leone, G; Pacifico, A, 2011) |
| "Vitiligo is a common, idiopathic skin disorder characterized by depigmented skin due to the loss of cutaneous melanocytes." | ( Gawkrodger, DJ; Ghosh, K; Kemp, EH; Kharkar, V; Khopkar, U; Patwardhan, M; Pradhan, V; Thakkar, V; Weetman, AP, 2013) |
| "Vitiligo is a chronic disease and can have significant impairment on patients' quality of life (QoL)." | ( Baba, R; Wong, SM, 2012) |
| "Vitiligo is an acquired multifocal and polygenic dyschromia that affects 1% to 3% of the world and presents as multiple depigmented macules and patches." | ( Cohen, GF; Paghdal, KV; Patel, NS, 2012) |
| "Vitiligo is an acquired pigmentary disorder caused by the destruction of melanocytes." | ( Choi, KW; Choi, SJ; Hong, JW; Jeon, SY; Kim, JH; Kim, KH; Lee, CY; Lee, KY; Song, KH, 2013) |
| "Vitiligo is characterized by a progressive loss of inherited skin color." | ( Gibbons, NC; Lüdemann, J; Martinez, A; Rokos, H; Salem, MA; Schallreuter, KU; Slominski, R, 2012) |
| "Vitiligo is characterized by a mostly progressive loss of the inherited skin color." | ( Elwary, SM; Gibbons, NC; Healey, AR; Maitland, DJ; Marsch, E; Salem, MA; Schallreuter, KU, 2012) |
| "Vitiligo is one of the most troubling diseases to both patient and physician." | ( Abdel Aal, HM; Abdel Hay, RM; Leheta, TM; Rashed, LA; Shahin, Z, 2012) |
| "Vitiligo is an acquired pigmentary disorder resulting from loss of melanocytes." | ( Begum, R; Dwivedi, M; Gokhale, RS; Imran, M; Laddha, NC; Mansuri, MS; Marfatia, YS; Rani, R; Sharma, VK; Singh, J, 2012) |
| "Vitiligo is characterized by depigmented skin patches caused by loss of epidermal melanocytes." | ( Manga, P; Orlow, SJ; Toosi, S, 2012) |
| "Vitiligo is an acquired depigmentation disorder affecting 0." | ( Goudi, D; Jahan, P; Mohammed, AW; Tippisetty, S, 2013) |
| "Vitiligo is characterized by a substantial loss of functional melanocytes in the epidermis and sometimes in hair follicles." | ( Ortonne, JP; Passeron, T, 2012) |
| "Vitiligo is a frequent dyschromia characterized by achromic macules that reflect the absence of melanocytes." | ( Xing, C; Xu, A, 2012) |
| "Vitiligo is a common, acquired, idiopathic depigmenting skin disorder." | ( Gawkrodger, DJ; Ghosh, K; Kemp, EH; Kharkar, V; Khopkar, U; Patwardhan, M; Pradhan, V; Taylor, LH; Teare, MD; Thakkar, V; Weetman, AP, 2013) |
| "Vitiligo is an acquired depigmentation disorder, and reactive oxygen species play an important role in melanocyte damage." | ( Gao, T; Guo, S; Huang, Y; Jian, Z; Li, C; Li, K; Li, Q; Li, X; Liu, L; Luan, Q; Qiang, H; Shi, Q; Wang, G; Wang, L; Wei, C; Yi, X, 2013) |
| "Vitiligo is considered to be an autoimmune disease and is known to be associated with other autoimmune diseases, particularly affecting the thyroid." | ( Bos, JD; Chandeck, C; Geskus, RB; Kroon, MW; Luiten, RM; van der Veen, JP; van Trotsenburg, P; Vrijman, C; Wind, BS; Wolkerstorfer, A, 2013) |
| "Vitiligo is an acquired, progressive depigmenting disorder that can induce autoimmune diseases." | ( Al-Benna, S; Dudda, M; Godau, P; Gothner, M; Schildhauer, TA, 2013) |
| "Vitiligo is a disorder of depigmentation, for which the pathogenesis is as yet unclear." | ( Antoniou, C; Miniati, A; Nicolaidou, E; Stratigos, AJ; Theoharides, TC; Therianou, A; Vasiadi, M; Weng, Z; Zhang, B, 2014) |
| "Vitiligo is caused by the destruction of melanocytes and results in the appearance of white patches on any part of the body, while alopecia areata is characterized by patchy hair loss primarily on the scalp, but may also involve other areas as well." | ( Harris, JE, 2013) |
| "Vitiligo is an autoimmune disorder that results in the destruction of melanocytes and subsequent skin depigmentation and hypopigmentation." | ( Cohen, PR; Jalalat, SZ, 2013) |
| "Vitiligo is an acquired and progressive hypomelanotic disease that manifests as circumscribed depigmented patches on the skin." | ( Barygina, V; Becatti, M; Cecchi, C; Fiorillo, C; Lotti, T; Nassi, P; Prignano, F; Silvestro, A; Taddei, N, 2014) |
| "Vitiligo is an acquired depigmentation disorder characterized by the loss of functional melanocytes from the epidermis." | ( Begum, R; Dave, DJ; Dwivedi, M; Gani, AR; Gupta, R; Khan, F; Laddha, NC; Madhavan, SE; Mansuri, MS; Marfatia, YS; Marfatia, Z; Panchal, VN; Patel, A; Singh, M; Yeola, AP, 2014) |
| "Vitiligo is a non contagious acquired pigmentation disorder with limited treatment possibilities." | ( Barot, BS; Parejiya, PB; Patel, HK; Shelat, PK; Shukla, A, 2014) |
| "Vitiligo is an acquired disorder of the skin and mucous membranes." | ( Hélou, J; Maatouk, I; Moutran, R; Obeid, G; Stéphan, F; Tomb, R, 2014) |
| "Vitiligo is the most common depigmentation disorder of the skin." | ( Darwish, HA; El-Sawalhi, MM; Gawdat, HI; Hegazy, RA; Mehaney, DA; Nooh, MM; Tawdy, AM, 2014) |
| "Vitiligo is a common pigmentary skin disorder of unknown etiology." | ( Al-Shobaili, HA; Rasheed, Z, 2014) |
| "Vitiligo is a depigmenting disorder resulting from loss of functional melanocytes in the skin." | ( Agarwal, N; Begum, R; Dwivedi, M; Laddha, NC; Mansuri, MS; Patel, HH; Shah, AM; Singh, M, 2014) |
| "Vitiligo is an autoimmune depigmentation disease, and defects in regulatory T cells (Tregs) have been proposed in the pathogenesis of generalized vitiligo (GV)." | ( Chattopadhyay, P; Gupta, S; Parihar, AS; Sharma, A; Sharma, VK; Tembhre, MK, 2015) |
| "Vitiligo is a common depigmentary skin disease that may follow a pattern of multifactorial inheritance." | ( Dang, N; Kong, Y; Liang, J; Wang, K; Wang, Y; Yang, H; Yang, X, 2015) |
| "Vitiligo is a common autoimmune disease of the skin that results in disfiguring white spots." | ( Agarwal, P; Essien, KI; Harris, JE; Hunter, CA; Pazoki-Toroudi, H; Randall, L; Rashighi, M; Richmond, JM, 2015) |
| "Vitiligo is a common, acquired depigmenting skin disorder." | ( Aydoğan, F; Bülbül Şen, B; Ekiz, Ö; Rifaioğlu, EN; Şen, T, 2014) |
| "Vitiligo is a pigmentation disorder of unknown aetiology, but it has been reported in association with other autoimmune diseases including type 1 diabetes mellitus (T1D)." | ( Al Salloom, A; Al-Shobaili, HA; Farhan, J; Meki, AR; Rasheed, Z; Zafar, U, 2014) |
| "Vitiligo is an acquired pigmentary disorder of unknown etiology that is clinically characterized by the development of white macules in the skin related to the selective loss of melanocytes in those areas." | ( Ding, G; Gong, Q; Li, X; Lu, Y; Sun, J; Zhao, W; Zhou, M, 2015) |
| "Vitiligo is a chronic skin disease characterized by the appearance of white depigmented lesion due to a loss of melanocytes." | ( Bilgiç, A; Bilgiç, Ö, 2015) |
| "Vitiligo is a common skin disorder affecting about 1 to 2% of the world population." | ( Bhattarai, CK; Ghimire, A; Jha, AK; Shrestha, S; Thapa, DP, 2014) |
| "Vitiligo is a refractory skin disease." | ( Furuhashi, T; Kato, H; Morita, A; Nakamura, M; Nishida, E; Ohguchi, R; Shintani, Y; Watanabe, S, 2015) |
| "Vitiligo is an acquired idiopathic cutaneous disease characterized by pearly white patches of variable shapes and sizes." | ( Abo Eittah, M; Hegazy, M; Samy, NA; Soliman, M, 2016) |
| "Vitiligo is presumed to be an autoimmune disorder in the dog; primary adrenal insufficiency (Addison's disease) is associated with immune-mediated destruction of the adrenal cortex." | ( Fracassi, F; Malerba, E; Morini, M, 2015) |
| "Vitiligo is a common condition that is often emotionally devastating for patients." | ( Craiglow, BG; King, BA, 2015) |
| "Vitiligo is a disorder with profound heterogeneity in its aetio-pathophysiology." | ( Abdel Hay, R; Fayez, S; Hasan, N; Mahmoud, R; Rashed, L; Zahra, A, 2015) |
| "Vitiligo is a common, acquired disorder of skin pigmentation that can significantly impact quality of life." | ( Cohen, BE; Elbuluk, N; Mu, EW; Orlow, SJ, 2015) |
| "Vitiligo is an inflammatory skin disorder in which activated T cells play an important role in its onset and progression." | ( Dong, X; Fu, L; Jin, R; Liu, D; Ning, W; Wang, S; Xu, A, 2015) |
| "Vitiligo is an acquired depigmenting disease with uncertain etiopathogenesis and the treatment modalities need to be consistently updated." | ( Chen, HD; Gao, XH; Li, L; Wu, Y, 2016) |
| "Vitiligo is a hypopigmentation disorder that is caused by the loss of melanocyte activity for melanin pigment generation." | ( Aggarwal, B; Sharma, CK; Sharma, M; Sharma, V, 2015) |
| "Vitiligo is an adverse reaction to be expected in patients treated with vemurafenib and whether its occurrence may be associated with a positive outcome, as suggested by previous investigations, is still a matter of debate." | ( Ferraù, F; Lacarrubba, F; Micali, G; Nasca, MR, 2016) |
| "Vitiligo is a polygenic autoimmune disorder characterized by loss of pigmentation due to melanocyte destruction." | ( Hu, WZ; Li, DG; Liu, W; Ma, HJ; Yang, QQ; Zhao, G, 2016) |
| "Facial vitiligo is associated with considerable psychological impact." | ( Chaiyabutr, C; Chanprapaph, K; Kanokrungsee, S; Vachiramon, V, 2016) |
| "Vitiligo is depigmenting disorder of the skin and mucous membranes but despite various therapeutic options, complete and satisfactory treatment of vitiligo still remains a challenge." | ( Korobko, I; Kovacevic, M; Lotti, T; Šitum, M; Stanimirovic, A, 2016) |
| "Pathogenesis of vitiligo is believed to be multifactorial disease with a wide variety of therapeutic modalities." | ( El Mofty, M; El Tawdy, A; Essmat, S; Helal, R; Mahgoub, D; Mashaly, HM; Ossama, S; Saad, A; Saney, I; Shaker, O; Sobeih, S; Youssef, R, 2016) |
| "Vitiligo is unsightly on darkly pigmented skin and leads important stigmatization because of the mix-up with leprosy." | ( Adégbidi, H; Atadokpèdé, F; Dégboé, B; do Ango-Padonou, F; Koudoukpo, C; Saka, B; Yédomon, H, 2017) |
| "The treatment of vitiligo is still one of the most difficult dermatological challenges, although there are many therapeutic options." | ( Li, R; Qiao, M; Sun, Q; Wang, X; Zhao, X, 2017) |
| "Vitiligo is an acquired pigmentary skin disorder which is disfiguring and difficult to treat." | ( Akhter, SM; Habibunnahar, M; Khatun, S; Nandi, AK; Paul, PC; Reza, AK; Roy, P; Saha, S; Saha, SK; Sultana, S, 2016) |
| "Vitiligo is an acquired condition characterized by depigmented, cutaneous lesions that result from the death of pigment-producing cells, melanocytes." | ( Jung, E; Kim, JH; Kim, MO; Lee, J; Lee, SY, 2017) |
| "Vitiligo is a multifactorial, autoimmune, depigmenting disorder of the skin where aberrant presentation of autoantigens may have a role." | ( Agrawal, B; Dani, P; Ghosh, P; Gokhale, RS; Gupta, S; Jaiswal, A; Kar, HK; Kumar, AA; Natarajan, VT; Patnaik, N; Rani, R; Sharma, A; Sharma, P; Sharma, VK; Singh, A; Vaish, U; Varkhande, SR; Verma, G, 2018) |
| "Though vitiligo is a common depigmentary disorder, it still represents a substantial therapeutic challenge." | ( Elias, PM; Lin, TK; Liu, J; Lv, C; Man, MQ; Xu, Y, 2017) |
| "Vitiligo is a pigmentary disorder and autoimmune pathogenesis seems most likely." | ( Bahadır, S; Karagüzel, G; Ökten, A; Sakarya, NP; Yaman, S, 2016) |
| "Vitiligo is an idiopathic systemic autoimmune disease affecting skin, hair and oral mucosa." | ( Hassan, SSU; Khan, H; Meher, BR; Patel, S; Rauf, A, 2017) |
| "Though vitiligo is an autoimmune disease, there is no current data to support systemic immunosuppressive monotherapy." | ( Garza-Mayers, AC; Kroshinsky, D, 2017) |
| "Vitiligo is a chronic, depigmenting skin disorder, whose pathogenesis is still unknown." | ( Aleksiejczuk, P; Borawska, MH; Niczyporuk, M; Ostrowska, J; Socha, K; Soroczyńska, J; Wacewicz, M, 2018) |
| "Vitiligo is a pigmentary disorder of skin affecting at least 1% of the world population of all races in both sexes." | ( Bafandeh, B; Bostakian, A; Faghihi, G; Hosseini, SM; Iraji, F; Jafari-Koshki, T; Mokhtari, F; Shahmoradi, Z, 2018) |
| "Vitiligo is a de-pigmenting skin disorder characterized by white patches on skin due to partial or complete loss of melanocytes." | ( Doppalapudi, S; Khan, W; Mahira, S, 2017) |
| "Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs." | ( Harris, JE; King, BA; Liu, LY; Refat, MA; Strassner, JP, 2017) |
| "Vitiligo is one of the commonest pigmentary disorders characterized by destruction of melanocytes." | ( Jha, AK; Prasad, S; Sinha, R, 2018) |
| "Vitiligo is characterized by death or functional defects of epidermal melanocytes through still controversial pathogenic process." | ( Bastonini, E; Bellei, B; Brown, DA; Cardinali, G; Cota, C; Dell'Anna, ML; Kovacs, D; Migliano, E; Mirabilii, S; Ottaviani, M; Picardo, M; Ricciardi, MR; Tafuri, A, 2017) |
| "Vitiligo is a long-term skin disease characterized by the loss of pigment in the skin." | ( Chen, H; Chen, HY; Tang, Y; Wang, JY; Wang, XQ; Wang, YY; Zhang, B; Zhang, M, 2017) |
| "Vitiligo is the most common acquired hypopigmentary disease in the community." | ( Abadi, A; Hoormand, M; Shafiee, A; Shahidi-Dadras, M, 2018) |
| "Vitiligo is an acquired skin disease characterized by depigmented areas of the skin." | ( Basnet, B; Bhushan, A; Gupta, S; Khan, R; Kumar, G; Sharma, A; Sharma, VK, 2018) |
| "Vitiligo is a common pigmentary disorder affecting about 1% of the general population." | ( Al-Shenawy, HA; Elgendy, HY; Hassan, GF; Ibrahim, ZA, 2019) |
| "Vitiligo is a common disease of unknown cause that produces disfiguring white patches of depigmentation that can be treated using various new and experimental therapies, such as narrow-band ultraviolet B (NB-UVB) microphototherapy, NB-UVB excimer laser, and monochromatic excimer light." | ( Barygina, V; Di Nardo, V; França, K; Lotti, T; Tirant, M; Valle, Y, 2019) |
| "Vitiligo is a depigmentation disorder of the skin." | ( Aisa, HA; Kabas, M; Lu, XY; Mamat, N, 2018) |
| "Acral vitiligo is a resistant subtype of vitiligo that does not respond easily to any treatment modality." | ( El-Zawahry, BM; Elmasry, MF; Ragab, A, 2019) |
| "Vitiligo is a disorder characterized by the decrease in melanin pigment of skin." | ( Karthika, C; Puttappa, N; Shivasaraun, UV; Sureshkumar, R, 2018) |
| "Vitiligo is an acquired cutaneous disorder of pigmentation, and the pathogenesis has remained elusive." | ( Cai, L; Ding, X; Hu, M; Li, X; Li, Z; Mei, E; Zhou, C, 2019) |
| "Vitiligo is a common depigmenting disease with complex pathogenesis." | ( Chandrashekar, BS; Harsha, S; Kusuma, MR; Madura, C, 2018) |
| "Vitiligo is a chronic skin disorder presenting with depigmentation, the pathogenesis of which is complex but the autoimmune theory is now preferred." | ( Czajkowski, R; Kosmalski, T; Kowaliszyn, B; Krysiński, J; Niezgoda, A; Winnicki, A, 2019) |
| "Vitiligo is an acquired depigmentary disorder resulting from disappearance of functional melanocytes in the involved skin." | ( Lan, CE; Yu, HS; Yu, S, 2019) |
| "Vitiligo is a common depigmentation disorder resulting from destruction of melanocytes, and has both genetic and environmental influences." | ( Li, Y; Liang, L; Tian, X; Zhong, L; Zhou, J, 2019) |
| "Vitiligo is an autoimmune disorder in which the predominant cause is an attack by CD8+ cytotoxic T cells on melanocytes in the epidermis." | ( Dina, Y; McKesey, J; Pandya, AG, 2019) |
| "Vitiligo is a disorder of dyspigmentation that can impact quality of life." | ( Griffith, J; Hamzavi, I; Mehta, C; Mehta, D; Mohammad, T; Nicholson, C, 2019) |
| "Vitiligo is a refractory disease in which treatment modalities are not yet established." | ( Andrianarison, M; Raharolahy, O; Rakotoarisaona, MF; Ramarozatovo, LS; Ranaivo, IM; Rapelanoro Rabenja, F; Razanakoto, NH; Sata, M; Sendrasoa, FA, 2019) |
| "Vitiligo is a depigmentation disorder that leads to serious psychological burden in patients, who are frequently reported to have depression and anxiety." | ( Doğan Günaydın, S; Gürpınar, A; Karaduman, A; Kılıç, C, 2019) |
| "Vitiligo is a commom disease of skin." | ( Peng, J; Xu, A; Yuan, Q; Zhong, L; Zhu, Y, 2019) |
| "Vitiligo is an acquired idiopathic pigmentary skin disorder characterized by the development of white macules and patches due to the loss of functioning melanocytes." | ( Konnikov, N; Turkowski, Y, 2019) |
| "Vitiligo is quite a common hypopigmentary disorder, which may affect both children and adults with important psychological effects due to the well-known leopard skin-like appearance." | ( Abdelmaksoud, A; Dave, DD; Lotti, T; Vestita, M, 2019) |
| "Vitiligo is a chronic cutaneous disease characterized with hypopigmented patches that leave psychological impact on the patients." | ( Eldelee, SA; Elfar, NN; Gheida, SF; Ibrahim, ZA; Sarhan, NI, 2021) |
| "Vitiligo is impacted by environmental triggers." | ( Akhtar, S; Cosgrove, C; Dellacecca, ER; Engelhard, VH; Knight, KL; Le Poole, IC; Mukhatayev, Z; Rademaker, AW, 2020) |
| "Vitiligo is common acquired pigmentary disorder affecting skin of 1% of the world population, India 3% to 8% incidences approximately." | ( Godse, K; Grandhi, S; Mahajan, S; Parsad, D; Pathak, R; Shah, B; Sharma, A; Shendkar, S; Teli, C, 2019) |
| "This type of vitiligo is sometimes termed figure-of-eight disease due to female predominance and perineal and perianal hypopigmentation or depigmentation around two orifices, the anal and vaginal introitus." | ( Silverberg, NB; Sink, JR, 2020) |
| "Vitiligo is a common depigmentary disease characterized as diagnosis simplicity and cure difficulty in view of the ambiguity of etiology, thus novel and effective treatments are urgently needed." | ( Cai, L; Chen, C; Chen, Z; Ding, X; Hu, M; Li, Z; Lin, L; Liu, J; Shao, J; Zheng, T, 2020) |
| "Vitiligo is an acquired, multifactorial disorder of the skin and mucous membranes." | ( Abdel Halim, DM; El Hadidi, H; El Tahlawi, S; Elgohary, SM; Ezzat, M; Fawzy, MM; Hegazy, RA; Sayed, KS; Shaker, O, 2020) |
| "Vitiligo is a chronic, autoimmune destruction of melanocytes, resulting in progressively expanding depigmented skin patches." | ( Feng, D; Lang, Y; Lin, M; Tu, C; Wang, J; Zhang, B; Zhang, D; Zhao, G, 2020) |
| "The pathogenesis of vitiligo is complex and multifactorial, accumulating evidence of increased oxidative stress and reduction in catalase levels in vitiligo patients has been shown, hence, pseudocatalase/superoxide dismutase (PSD) gel has been used as treatment option for vitiligo." | ( Al-Qarqaz, FA; Al-Sheyab, RF; Alkhader, YS; Alshiyab, DM; Jafaar, SI; Muhaidat, JM, 2022) |
| "Vitiligo is a skin disorder commonly acquired." | ( Khater, M; Khattab, FM; Nasr, M; Salah, S, 2020) |
| "Vitiligo is a depigmentation disorder that develops as a result of the progressive disappearance of epidermal melanocytes." | ( Chen, J; Cui, T; Gao, T; Jian, Z; Li, C; Li, K; Li, S; Liu, L; Ni, Q; Song, P; Tian, Y; Yi, X; Zhang, W; Zhuang, T, 2020) |
| "Vitiligo is an autoimmune disease characterized by patches of depigmentation." | ( Abdelgawad, NH; Elsaie, ML; Elshahed, AR; Jafferany, M; Nada, AS; Zaki, AM, 2020) |
| "Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and reduced quality of life." | ( Butler, K; Gottlieb, AB; Grimes, P; Hamzavi, I; Harris, JE; Howell, MD; Ji, T; Kuo, F; Lebwohl, M; Pandya, AG; Rosmarin, D; Sun, K, 2020) |
| "Vitiligo is a common acquired pigmentary disorder." | ( Kanokrungsee, S; Pruettivorawongse, D; Rajatanavin, N, 2021) |
| "Vitiligo is a depigmentation disease characterized by gradual loss of melanin and melanocytes from the epidermis." | ( Abe, Y; Hozumi, Y; Okamura, K; Suzuki, T, 2020) |
| "Vitiligo is a depigmenting skin disorder that can cause significant patient distress." | ( Steuer, AB; Zampella, JG, 2020) |
| "Since vitiligo is widely considered as an autoimmune disease, this study was an attempt to understand miR-2909 RNomics in vitiligo pathogenesis using MBEH treated primary melanocytes as an archetype cellular model because MBEH causes pathological features indistinguishable from clinical vitiligo." | ( Kaul, D; Kaushik, H; Kumaran, MS; Parsad, D, 2020) |
| "Vitiligo is an acquired, depigmenting skin disease with unclear, multifactorial etiopathogenesis affecting not only skin but also connected with metabolic abnormalities, including glucose and lipid abnormalities, confirming the systemic nature of the disease." | ( Haldar, D; Kaur, C; Patel, S; Taneja, J; Taneja, K, 2020) |
| "Vitiligo is associated with oxidant stress and α-lipoic acid (ALA) is an antioxidative agent." | ( Chen, X; Gao, XH; Gu, H; Guan, X; Lu, H; Sun, Y; Wang, H; Wu, Y; Yao, Z; Zeng, F; Zhang, J, 2021) |
| "Psoriasis and vitiligo are common, autoimmune skin diseases, their etiology is still unclear." | ( Borawska, MH; Niczyporuk, M; Socha, K; Soroczyńska, J; Wacewicz-Muczyńska, M, 2021) |
| "Vitiligo is an autoimmune skin condition characterized by depigmented macules and patches, and has a huge psychosocial impact on patients." | ( Al-Niaimi, F; Ali, FR; Searle, T, 2021) |
| "Vitiligo is autoimmune, acquired, idiopathic, chronic, and progressive de/hypopigmentary cutaneous condition that targets the cell-producing pigment called melanin." | ( Arora, N; Mehan, S; Siddiqui, EM, 2021) |
| "Vitiligo is a prevalent destructive melanocyte skin disease that negatively affects the patients' life in terms of self-esteem." | ( Asilian, A; Iraji, F; Kazemipour, S; Mohaghegh, F; Mokhtari, F; Mozafarpoor, S; Shahmoradi, Z; Talakoub, M, 2021) |
| "Vitiligo is an autoimmune disease in which pigment is lost in patches of the skin." | ( He, M; Lin, M; Liu, D; Tu, C; Zhang, B; Zhang, X, 2021) |
| "Vitiligo is an acquired pigmentation disorder due to loss of melanocytes." | ( Ahmed, FS; Esmat, SM; Gawdat, HI; Hegazy, RA; Said, ER, 2021) |
| "Vitiligo is a common depigmenting condition that carries a high psychosocial morbidity, especially when it occurs over exposed areas like lips." | ( Deshpande, AJ, 2020) |
| "Vitiligo is an autoimmune disease characterized by depigmented patches of skin due to loss of the pigment-producing melanocytes." | ( Anderson, ZT; Corder, KM; Dobrunz, LE; Harris, ML; Mehl, J, 2021) |
| "Melasma and vitiligo are both common pigmentary disorders, and the treatment is challenging." | ( Chiang, PH; Chiu, YC; Chung, WH; Ku, CL; Lin, YJ; Ng, CY, 2021) |
| "Vitiligo is an acquired autoimmune skin disorder with depigmented macules and patches." | ( Rahimi, H; Tehranchinia, Z; Zeinali, R, 2021) |
| "Vitiligo is an autoimmune and acquired disease characterized by the destruction of epidermal melanocytes leading to depigmentation of the skin." | ( Jalalmanesh, S; Mansouri, P; Monji, F; Rajabi, M, 2022) |
| "Vitiligo is a depigmentation disorder that affects 0." | ( El-Hadidy, WF; Elhalmoushy, PM; Elnaggar, YSR; Elsheikh, MA; Kamel, MA; Matar, NA; Omran, GA, 2022) |
| "Vitiligo is a pigmentary disorder resulting from progressive destruction of melanocytes in the skin." | ( Aryanian, Z; Azizpour, A; Farzaneh, S; Goodarzi, A; Hatami, P; Shirzadian, A, 2022) |
| "Vitiligo is a depigmented skin disorder caused by a variety of factors, including autoimmune, metabolic disturbance or their combined effect, etc." | ( Chen, J; Cui, T; Du, P; Li, B; Li, C; Li, S; Ni, Q; Wang, Q; Ye, Z; Yi, X; Zhang, Z, 2022) |
| "The treatment of vitiligo is often challenging to dermatologists." | ( Chen, Y; Hu, Y; Luo, H; Song, X; Xie, B; Xu, J; Zhao, Y, 2022) |
| "Vitiligo is a condition which may affect individual at any age and carries risk of developing metabolic syndrome in future." | ( Dubey, A; Gourh, V, 2022) |
| "Vitiligo is a common cutaneous depigmentation disorder." | ( Chang, HC; Guo, SP, 2022) |
| "Vitiligo is an acquired skin depigmentation disorder related to the destruction of melanocytes." | ( Altunay, IK; Erdem, Y; Ozkur, E; Tuncel, D; Ugurer, E, 2022) |
| "Vitiligo is an acquired depigmenting disorder in which destruction of skin melanocytes." | ( Chen, S; Gao, Y; Jin, W; Lu, Y; Wu, J; Zhou, F, 2022) |
| "Vitiligo is a multifactorial, acquired skin disease of unknown etiology characterized by depigmented patches caused by melanocyte loss." | ( Demirbaş, A; Eker, H, 2022) |
| "Vitiligo is a depigmentation disease which affects skin and hair follicles with a prevalence of 0." | ( Erdoğan, A; Mutlu, HS; Solakoğlu, S, 2022) |
| "Acral lesions of vitiligo are most likely recalcitrant to the known lines of treatment." | ( Abdelhamid, MF; El Desouky, ED; Ramez, SA; Sayed, KS; Weshahy, R, 2022) |
| "Vitiligo is an autoimmune-related disease with a complex aetiology that involves innate immunity." | ( Feng, Q; Geng, S; Huo, X; Li, Y; Sun, J; Sun, L; Xie, X, 2022) |
| "Vitiligo is a common depigmentation skin disease that affects the quality of life in many patients." | ( Al-Akayleh, F; Ghanim, BY; Hajleh, MNA; Issa, R; Qinna, NA; Ubaydee, AHN, 2022) |
| "Vitiligo is a chronic treatment-resistant autoimmune disorder characterized by circumscribed depigmented maculae." | ( Hu, Z; Liu, Y; Song, H; Wang, T; Yang, L; Zhang, S, 2022) |
| "Vitiligo is a noncontagious autoimmune skin depigmenting disease." | ( Dwivedi, M; Giri, PS; Mistry, J, 2022) |
| "Acral vitiligo is often resistant to medical and surgical treatments." | ( Albalat, W; Ehab, R; Elsayed, M; Fawzy, M; Salem, A, 2022) |
| "Although vitiligo is not associated with increased mortality risk, its development is associated with increased psychological stress." | ( Abdeen, M; Asawa, P; Felton, K; Khan, C; Lister, J; Rinchuse, D; Samhouri, Y; Vusqa, UT, 2022) |
| "Vitiligo is a chronic autoimmune disease that causes skin depigmentation." | ( Butler, K; Desai, SR; Ezzedine, K; Grimes, P; Harris, JE; Kornacki, D; Lebwohl, M; Pandya, AG; Passeron, T; Rosmarin, D; Ruer-Mulard, M; Seneschal, J; Sun, K; Wolkerstorfer, A, 2022) |
| "Vitiligo is one of the most challenging dermatological diseases with little improvement promises." | ( Abdelaleem, HL; Saad, MA; Tawfik, KM, 2023) |
| "Vitiligo is an autoimmune disease where its current treatment strategies are lengthy in course and do not guarantee complete cure." | ( Abdel-Halim, M; Hathout, RM; Hesham, H; Mansour, S; Rady, M, 2022) |
| "Vitiligo is a complex disease wherein derangements in multiple pathways determine the loss of functional melanocytes." | ( Bellei, B; Caputo, S; Cigliana, G; D'Arino, A; Iacovelli, P; Migliano, E; Ottaviani, M; Pacifico, A; Papaccio, F; Picardo, M; Sciuto, L; Truglio, M, 2022) |
| "Vitiligo is a complex disease wherein derangements in multiple pathways determine the loss of functional melanocytes." | ( Bellei, B; Caputo, S; Cigliana, G; D'Arino, A; Iacovelli, P; Migliano, E; Ottaviani, M; Pacifico, A; Papaccio, F; Picardo, M; Sciuto, L; Truglio, M, 2022) |
| "Vitiligo is a complex disease wherein derangements in multiple pathways determine the loss of functional melanocytes." | ( Bellei, B; Caputo, S; Cigliana, G; D'Arino, A; Iacovelli, P; Migliano, E; Ottaviani, M; Pacifico, A; Papaccio, F; Picardo, M; Sciuto, L; Truglio, M, 2022) |
| "Vitiligo is a complex multifactorial disorder of depigmentation affecting 0." | ( Deverapalli, S; Kahn, J; Rosmarin, D, 2022) |
| "Vitiligo is a complex multifactorial disorder of depigmentation affecting 0." | ( Deverapalli, S; Kahn, J; Rosmarin, D, 2022) |
| "Vitiligo is a hypopigmentation disease characterized by melanocyte death in the human epidermis." | ( Enami, H; Hirobe, T, 2022) |
| "Vitiligo is a hypopigmentation disease characterized by melanocyte death in the human epidermis." | ( Enami, H; Hirobe, T, 2022) |
| "Vitiligo is a common depigmenting skin disease that is often difficult to treat." | ( Fujimoto, M; Kume, M; Tanaka, A; Tanemura, A; Watanabe, R; Yamane, S; Yokoi, K, 2023) |
| "Vitiligo is a common depigmenting skin disease that is often difficult to treat." | ( Fujimoto, M; Kume, M; Tanaka, A; Tanemura, A; Watanabe, R; Yamane, S; Yokoi, K, 2023) |
| "Vitiligo is a common skin disease with a complex pathogenesis, and so far, no effective treatment is available." | ( Gu, Y; Ke, Y; Li, H; Li, Y; Li, Z; Liang, B; Lu, Y; Peng, L; Zhu, H, 2023) |
| "Vitiligo is an incurable, slowly progressive skin condition, the prevalence of which ranges from 0." | ( Chirino-Castillo, GQ; Guerrero-Oliva, G; Marín-Rivera, D; Morales-Sánchez, MA; Núñez-Benítez, MA; Peralta-Pedrero, ML; Santa-Cruz, FJ, 2022) |
| "Vitiligo is an autoimmune skin disorder characterized by circumscribed depigmented macules and patches caused by the loss of functional melanocytes." | ( Hadibarhaghtalab, M; Hatami, M; Parvar, SY; Pazyar, N; Radmanesh, M; Yaghoobi, R, 2023) |
| "Vitiligo is a depigmenting disorder caused by the destruction of melanocytes by various mechanisms which affect melanocyte function and survival." | ( Adel Abd El Azim, A; Galal, SA; Salem, MW, 2023) |
| "Vitiligo is a depigmenting disorder resulting from loss of functional melanocytes in the skin." | ( Borzęcki, A; Nieradko-Iwanicka, B; Przybylska, D, 2023) |
| "Vitiligo is a recalcitrant depigmentary autoimmune skin disorder." | ( Darchini-Maragheh, E; Fathi-Najafi, S; Layegh, P; Meshkat, M; Rahsepar, S; Sazgarnia, S; Sepehr, V, 2022) |
| "Vitiligo is a disorder characterized by loss of epidermal melanocytes, resulting in depigmented macules and patches." | ( Haddadin, R; Kundu, RV; LeWitt, T; Obiofuma, G; Peterson, J; Tauscher, R, 2023) |
| "Vitiligo is a common primary, limited or generalized skin depigmentation disorder." | ( Dong, J; Lai, Y; Shang, J; Yue, Y; Zhang, X; Zhong, H, 2023) |
| "Vitiligo is a chronic autoimmune skin disorder whose diagnosis is often psychologically upsetting." | ( Alberti-Violetti, S; Avallone, G; Conforti, C; Maronese, CA; Marzano, AV; Mattioli, MA; Quaglino, P; Ribero, S; Roccuzzo, G; Tavoletti, G; Zalaudek, I, 2023) |
| "Vitiligo is an immune-mediated skin disorder that targets epidermal melanocytes leading to the appearance of depigmented skin patches." | ( Ammar, AM; Elrewiny, EM; Mansour, M; Mohamed, SFF; Rageh, MA; Shawky, A, 2023) |
| "Acral vitiligo is a significantly distressing condition and tends to be treatment-resistant." | ( Bishnoi, A; Kumar, D; Parsad, D; Sendhil Kumaran, M; Subburaj, K; Thakur, V; Vinay, K, 2023) |
| "Vitiligo is a type of hypomelanosis." | ( Borzova, VA; Buglak, AA; Telegina, TA; Vechtomova, YL, 2023) |
| "Vitiligo is an acquired skin disease with a worldwide prevalence of 0." | ( Heidari, S; Hosseini, ZSS; Lajevardi, V, 2023) |
| "Vitiligo is an acquired chronic depigmentary disorder affecting approximately 0." | ( Fu, D; Gong, Y; Jian, Y; Li, Y; Shi, H; Wang, X, 2023) |
| "Vitiligo is a common autoimmune skin disease caused by autoreactive CD8+ T cells." | ( Deng, Y; Li, D; Liu, Z; Nie, X; Pan, R; Shi, Z; Wang, T; Wei, Y; Zeng, Y; Zhang, R, 2023) |
| Excerpt | Reference |
|---|
| "This drug is widely used in the treatment of vitiligo and psoriasis." | ( Dudek, G; Mandula, BB; Pathak, MA, 1976) |
| "After the end of diphencyprone treatment, vitiligo had a spontaneous significant improvement only in the man." | ( Gourgiotou, K; Hatzis, J; Stratigos, J; Tosca, A; Varelzidis, A, 1988) |
| "PUVA therapy is effective in the treatment of vitiligo and hypopigmented scars." | ( Berakha, GJ; Lefkovits, G, 1985) |
| "Although the treatment of vitiligo with plants containing photodynamically active compounds dates back as far as 1400 BC, the modern period of research began only in the 1930's leading to the development of oral psoralens, a coumarin derivative." | ( Forrest, HJ; Forrest, JB, 1980) |
| "For an effective treatment of vitiligo, it is as important to arrest the progression of the disease (if it is still active) as it is to induce repigmentation in existing lesions." | ( Khera, V; Pasricha, JS, 1994) |
| "The efficacy of IPD in treating vitiligo was thought to be due to the suppressive effect of this drug on IL-4 production." | ( Kaneko, F; Nihei, Y; Nishibu, A, 1998) |
| "Following steroid treatment, the vitiligo remitted, but reappeared later." | ( Abe, S; Nishikatsu, H; Yasui, T, 1998) |
| "Lesion spreading during treatment of vitiligo was also observed in 7 (19%) patients in 1 study." | ( Goa, KL; McNeely, W, 1998) |
| "The efficacy of MF in treatment of vitiligo was proven to be due to the stimulatory effect of melanocyte proliferation and melanin production via alpha-MSH." | ( Ichimiya, M, 1999) |
| "Guidelines for the treatment of vitiligo can be successfully developed and disseminated for daily clinical practice." | ( Bos, JD; Bossuyt, PM; Njoo, MD; Westerhof, W, 1999) |
| "PUVA therapy remains a primary treatment for vitiligo, despite unsatisfactory results." | ( Akan, T; Atakan, N; Bükülmez, G; Karaduman, A; Kölemen, F; Sahin, S; Yalçin, B, 2001) |
| "The surface area of treated vitiligo sites ranged from 0." | ( Acikel, C; Celikoz, B; Ulkur, E, 2003) |
| "This combination was an effective treatment for vitiligo, especially in initiating repigmentation." | ( Azaiz, MI; Ben Hamida, A; Ben, O; Cherif, F; Dhari, A, 2003) |
| "Although the results obtained in the treatment of vitiligo are promising, they have to be confirmed in larger cohorts and ensure the absence of median and long term side effects." | ( Ortonne, JP; Passeron, T, 2005) |
| "Aspirin-treated vitiligo patients showed significant decrease in serum V-IgG activity and sIL-2R concentration (0." | ( Zailaie, MZ, 2005) |
| "Low-dose oral aspirin treatment of active vitiligo patients can cause significant reduction in the acute serum immunologic markers of T cell activation, V-IgG activity and sIL-2R concentration with concomitant arrest of disease activity." | ( Zailaie, MZ, 2005) |
| "The current treatment of vitiligo is not satisfactory according to the opinions of both the patient population and the dermatologists." | ( Assad, GB; Buggiani, G; De Giorgi, V; Delescluse, J; Hercogova, J; Lotti, T; Troiano, M, 2008) |
| "We reviewed the treatment of vitiligo with topical immunomodulators and topical steroids to evaluate the efficacy of immunomodulators in treatment of vitiligo." | ( Bak, H; Chang, SE; Choi, CW; Choi, JH; Huh, CH; Kim, BJ; Kim, CW; Kim, MN; Kim, SE; Mun, SK; Park, HS, 2008) |
| "Current treatments for vitiligo, a common pigmentary disorder affecting around 1% of the world's population, are largely unsatisfactory." | ( Ashcroft, DM; González, U; Whitton, ME, 2008) |
| "We propose that the successful treatment of vitiligo with topical tacrolimus involves the unique immunosuppressive actions of the T lymphocyte T-helper (Th) 2 cytokine, interleukin (IL)-10." | ( Dytoc, MT; Lauzon, G; Maguiness, S; Taher, ZA, 2009) |
| "A few studies on the treatment of vitiligo with topical tacrolimus have been published and showed promising results." | ( Breier-Maly, J; Hoenigsmann, H; Kittler, H; Konschitzky, R; Radakovic, S; Sator, P; Tanew, A, 2009) |
| "Current treatments for vitiligo are largely unsatisfactory." | ( Berti, S; Buggiani, G; Lotti, T, 2009) |
| "Topical treatments used in the treatment of vitiligo include steroids, calcineurin inhibitors, vitamin D analogues, pseudocatalase, and depigmenting agents." | ( Halder, RM; Hossani-Madani, AR, 2010) |
| "All of the patients would recommend the treatment to other vitiligo patients." | ( Assen, YJ; Bjerring, P; de Leeuw, J; Martino Neumann, HA; van der Beek, N, 2011) |
| "Topical tacrolimus is an effective treatment for vitiligo irrespective of skin tone, with greatest benefit in Fitzpatrick type 3-4 skin." | ( Silverberg, JI; Silverberg, NB, 2011) |
| "Traditionally, the treatment of vitiligo has focused on pharmacologic interventions, but nearly half of all treated patients fail to respond successfully." | ( Cohen, GF; Paghdal, KV; Patel, NS, 2012) |
| "Our ability to treat vitiligo may be imperfect, but through appropriate patient selection and careful application of one or more of these advanced therapies, successful treatment of vitiligo, even in patients refractory to treatment, can be achieved." | ( Cohen, GF; Paghdal, KV; Patel, NS, 2012) |
| "While the goal of available treatment in vitiligo is to regain pigmentation, some patients affected by extensive and treatment-resistant vitiligo, with a major social and emotional impact, may benefit from depigmentation therapy." | ( Boniface, K; Ezzedine, K; Seneschal, J; Taieb, A, 2014) |
| "We sought to identify new treatments for vitiligo, and first considered repurposed medications because of the availability of safety data and expedited regulatory approval." | ( Agarwal, P; Essien, KI; Harris, JE; Hunter, CA; Pazoki-Toroudi, H; Randall, L; Rashighi, M; Richmond, JM, 2015) |
| "LT could be a promising treatment for vitiligo, especially the periocular variant." | ( Abdel-Rahman, AT; Anbar, TS; El-Ammawi, TS; Hanna, MR, 2015) |
| "Conventional treatment of vitiligo on hands and feet often produces an unsatisfactory result." | ( Chaiyabutr, C; Kanokrungsee, S; Rattanaumpawan, P; Vachiramon, V, 2016) |
| " BACKGROUND: Treatment of vitiligo is aimed at repigmentation and often consists of multiple modalities, none of which are universally or rapidly successful." | ( Garza-Mayers, AC; Kroshinsky, D, 2017) |
| "Systemic drug treatment of vitiligo is currently limited to predominantly adjuvant measures for increasing the effectiveness of UV light therapy." | ( Ceric-Dehdari, P; Meurer, M, 2017) |
| "Bimatoprost seems to be promising in treating stable vitiligo but large-scale studies are required." | ( Jha, AK; Prasad, S; Sinha, R, 2018) |
| "The goal of treating vitiligo is to make it less noticeable either by restoring lost pigment or by eliminating remaining pigment." | ( Barygina, V; Di Nardo, V; França, K; Lotti, T; Tirant, M; Valle, Y, 2019) |
| "There is currently no definitive treatment for vitiligo; various modalities include immune modulators phototherapy and skin camouflage." | ( Arora, CJ; Gupta, M; Rafiq, M; Shumack, S, 2020) |
| "Latanoprost proved effective in treating vitiligo disease involving eyelids." | ( Ghasemzadeh Diva, SM; Goldust, M; Goren, A; Hosseini, A; Lotti, T; Morteza-Semnani, K; Nowroozpoor Dailami, K; Rahmatpour Rokni, G; Rathod, D; Sadeghi, Z; Saeedi, M; Sonthalia, S; Vojvodic, A, 2020) |
| "In Unani system of medicine the treatment of Bars (Vitiligo) starts with removal of harmful materials from the body with Munzij and Mushil (MM), a poly herbal Unani formulation." | ( Chakraborthy, A; Husain, GM; Jabeen, F; Rafeeqi, TA; Waheed, MA, 2020) |
| "There is no approved treatment for vitiligo repigmentation and current off-label therapies have limited efficacy, emphasising the need for improved treatment options." | ( Butler, K; Gottlieb, AB; Grimes, P; Hamzavi, I; Harris, JE; Howell, MD; Ji, T; Kuo, F; Lebwohl, M; Pandya, AG; Rosmarin, D; Sun, K, 2020) |
| "Despite the recent advances in the treatment of vitiligo, results are still largely unsatisfactory and many patients show either weak or no response to treatment." | ( Alakad, R; Fawzy, MM; Nofal, A, 2021) |
| "Thus, it can be an alternative treatment for vitiligo especially when the latter is resistant to conventional therapies." | ( Bazzi, N; Habre, M; Maalouf, D; Salloum, A, 2020) |
| "Conventional methods of treatment for vitiligo are often unsatisfactory to the patients and time consuming, new treatment modalities are needed." | ( Abdel-Gaber, RM; Bakr, RM; Tawfik, YM, 2021) |
| "FUE is an effective method of surgical treatment of stable vitiligo, and topical CBD as a new adjuvant therapy is successful in targeting the immunological background of vitiligo." | ( Abd Elazim, NE; Abdel Gaber, RM; El-Deek, HEM; Fathy, E; Kamal, A, 2021) |
| "There are several possible treatments for vitiligo, none of which could be considered as a definitive cure." | ( Rahimi, H; Tehranchinia, Z; Zeinali, R, 2021) |
| "Although there is no definitive treatment for vitiligo, several treatment options have been associated with relative satisfactory outcomes." | ( Hadibarhaghtalab, M; Hatami, M; Parvar, SY; Pazyar, N; Radmanesh, M; Yaghoobi, R, 2023) |
| "However, the treatment of vitiligo combined with COVID-19 has not been reported." | ( Chi, J; Ding, M; Li, Q; Li, Z; Wang, T; Wang, Y; Zhang, Y, 2023) |
| "Six common CPMs for treating vitiligo were selected in our study, and 48 targeted articles and 4446 patients were included." | ( Si, G; Wang, D; Wang, J, 2023) |